Potassium Chloride Injection

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L, while the main cation outside cells is sodium ions, and the serum potassium concentration is only 3.5-5.0 mmol/L. The body mainly relies on Na+-K+ ATPase on the cell membrane to maintain the difference in K+ and Na+ concentrations inside and outside cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference inside and outside the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal potassium ion concentration and concentration difference inside and outside cells are closely related to certain functions of cells, such as carbohydrate metabolism, glycogen storage and protein metabolism, excitability and conductivity of nerves and muscles including myocardium, etc.

Potassium chloride

Electrolyte supplement. Used for: 1. Treatment of hypokalemia caused by various reasons. Such as insufficient food intake, vomiting, severe diarrhea, use of potassium-excreting diuretics, hypokalemic familial periodic paralysis, hypokalemia caused by long-term use of glucocorticoids and supplementation of hypertonic glucose, etc. 2. Prevention of hypokalemia. When the patient has potassium loss, especially if hypokalemia is harmful to the patient (such as patients using digitalis drugs), preventive potassium salt supplementation is required, such as eating very little, severe or chronic diarrhea, long-term use of adrenocortical hormones, potassium-losing nephropathy, Bartter syndrome, etc. 3. Frequent, multifocal premature beats or rapid arrhythmias caused by digitalis poisoning.

Used for patients with severe hypokalemia or those who cannot take it orally. The general usage is to add 10-15ml of 10% potassium chloride injection to 500ml of 5% glucose injection and drip (avoid direct intravenous drip and push injection). The dose, concentration and speed of potassium supplementation are determined according to the clinical condition, blood potassium concentration and improvement of the potassium deficiency pattern on the electrocardiogram. The potassium concentration should not exceed 3.4g/L (45mmol/L), the potassium supplementation rate should not exceed 0.75g/hour (10mmol/hour), and the daily potassium supplementation amount should be 3-4.5g (40-60mmol). When potassium deficiency in the body causes severe rapid ventricular ectopic arrhythmias, such as torsades de pointes, short bursts, recurrent multiline ventricular tachycardia, ventricular flutter and other life-threatening severe arrhythmias, the potassium salt concentration should be high (0.5

Clinical trials have found that this product is well tolerated, with mild and transient adverse reactions that generally do not require discontinuation of treatment. The overall incidence of adverse reactions with this product is similar to that with placebo. In controlled clinical studies of essential hypertension, the only adverse reaction with an incidence ≥1%, drug-related, and higher than placebo was dizziness. In addition, less than 1% of patients experienced dose-related orthostatic hypotension. Although the incidence of rash in controlled clinical trials is lower than that of placebo, there have been individual reports. In these double-blind controlled clinical studies of essential hypertension, adverse reactions with an incidence of 1% or more after the use of this product, regardless of whether they were drug-related, included, in addition to the adverse events mentioned above, at least two patients/subjects in clinical studies experienced potentially serious adverse events or incidences after using losartan

1. Patients with hyperkalemia. 2. Patients with acute renal insufficiency or chronic renal insufficiency are contraindicated.

Precautions for children: Precautions for pregnancy and lactation: No special findings. Precautions for the elderly: The kidney's K+ clearance function of the elderly is reduced, and hyperkalemia is more likely to occur when potassium salts are used.

1. Adrenal glucocorticoid drugs, especially those with more obvious mineralocorticoid effects, adrenal mineralocorticoids and adrenocorticotropic hormone (ACTH), can promote urinary potassium excretion, and when used in combination with this product, the efficacy of potassium salts is reduced. 2. Anticholinergic drugs can aggravate the gastrointestinal irritation of oral potassium salts, especially potassium chloride. 3. Non-steroidal anti-inflammatory analgesics aggravate the gastrointestinal reactions of oral potassium salts. 4. When used in combination with stored blood (30mmol/L of potassium for less than 10 days of storage, 65mmol/L of potassium for more than 10 days of storage), potassium-containing drugs and potassium-sparing diuretics, the chance of hyperkalemia increases, especially in patients with renal damage. 5. Angiotensin-converting enzyme inhibitors and cyclosporin A can inhibit aldosterone secretion and reduce urinary potassium excretion, so hyperkalemia is likely to occur when used in combination. 6. Heparin can inhibit the synthesis of aldosterone and reduce urinary potassium excretion, so hyperkalemia is likely to occur when used in combination. In addition, heparin can increase the chance of gastrointestinal bleeding.

Keep tightly closed.

10ml:1g

36 months

Tonghua Huaxia Pharmaceutical Co., Ltd.

• Founded in:

  2001-12-25

• Address:

  Liming Industrial Zone, Kuaidamao Town, Tonghua County, Jilin Province

• Tax NO.:

  91220521732563319H

• Registered Funds:

  95 million yuan

• Website:

  Log in to view

• Email:

  Log in to view